Healthcare Market Trends

Healthcare Market Trends & Clinic Economics

Sourced analysis of healthcare business trends relevant to independent medical practices, telehealth operators, medical spas, and healthcare entrepreneurs. Verifiable statistics with clear source citations. AJ's operator analysis is clearly identified.

Market statistics are sourced from cited publications and research. Projections and estimates reflect source data at the time of publication. AJ's Take sections represent operator analysis, not investment advice or clinical guidance.

Weight Management

GLP-1 Market Growth

The GLP-1 receptor agonist market has experienced rapid growth driven by FDA approvals of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) for type 2 diabetes and obesity. The global GLP-1 market was valued at approximately $24 billion in 2023 and is projected to exceed $100 billion by 2030 according to multiple analyst estimates. Compounded GLP-1 demand surged during the FDA shortage period and remains significant despite the shortage resolution.

Key Facts

  • ◆Novo Nordisk and Eli Lilly dominate the branded GLP-1 market with semaglutide and tirzepatide respectively.
  • ◆FDA removed semaglutide and tirzepatide from the drug shortage list in early 2025, ending the shortage-based compounding authorization.
  • ◆Compounded GLP-1 demand from 503A pharmacies continues under personalization and clinical need arguments.
  • ◆Retatrutide (LY3437943), a triple GIP/GLP-1/glucagon receptor agonist, is in Phase 3 clinical trials as of 2026.

Operator Impact

Clinic operators in the weight management space must navigate the post-shortage compounding landscape, branded product access and pricing, and emerging pipeline candidates. Business models built entirely on compounded GLP-1 revenue face regulatory uncertainty.

Telehealth

Telehealth Market Stabilization

The telehealth market expanded dramatically during the COVID-19 public health emergency and has stabilized at a higher baseline than pre-pandemic levels. McKinsey estimated that telehealth utilization stabilized at 38 times pre-pandemic levels. The expiration of PHE flexibilities has created regulatory uncertainty for telehealth prescribing of controlled substances, interstate practice, and Medicare reimbursement.

Key Facts

  • ◆DEA proposed rules for telemedicine prescribing of controlled substances remain pending finalization as of November 2026.
  • ◆Medicare telehealth coverage extensions have been renewed multiple times; current extensions require monitoring.
  • ◆Interstate medical licensure compact (IMLC) membership has expanded, simplifying multi-state telehealth practice for physicians.
  • ◆Direct-to-consumer telehealth platforms have faced increased FTC scrutiny over advertising and subscription practices.

Operator Impact

Telehealth operators must track DEA final rules on controlled substance prescribing, Medicare telehealth coverage extensions, and state-specific telehealth practice requirements. Operators prescribing testosterone, buprenorphine, or stimulants via telehealth face the highest regulatory exposure.

Medical Directorship

Medical Directorship Market

Demand for medical directors and collaborating physicians has grown alongside the expansion of nurse practitioner-owned and PA-owned practices, med spas, IV therapy clinics, and telehealth companies. Medical directorship compensation varies significantly by practice type, state supervision requirements, and scope of oversight. The market is fragmented with no standardized compensation benchmarks.

Key Facts

  • ◆NP full practice authority states do not require physician collaboration for NP-owned practices, reducing medical director demand in those states.
  • ◆Reduced and restricted practice states require physician collaboration agreements, creating ongoing demand for medical directors.
  • ◆Corporate Practice of Medicine (CPOM) laws in states like California, Texas, and New York require physician ownership of professional entities, affecting MSO/PLLC structures.
  • ◆Doctor Staffers (doctorstaffers.com) operates a nationwide medical directors network connecting physicians with practices.

Operator Impact

Clinic operators seeking medical directors must understand state-specific supervision requirements, CPOM rules, and appropriate compensation structures. Underpaying or over-relying on a medical director creates both regulatory and liability exposure.

Med Spa & Aesthetics

Med Spa Industry Growth

The medical spa industry has grown significantly, with the American Med Spa Association reporting industry revenue exceeding $19 billion in 2023. Med spas offering aesthetic treatments including injectables, laser procedures, and body contouring operate in a complex regulatory environment that varies significantly by state.

Key Facts

  • ◆Med spa ownership and supervision requirements vary by state; many states require physician ownership or supervision for certain procedures.
  • ◆Laser and energy-based device operation requirements vary by state, with some requiring physician supervision and others permitting RN or esthetician operation.
  • ◆Injectables (Botox, fillers) require medical oversight in all states; the level of required oversight varies.
  • ◆The FTC has increased scrutiny of med spa advertising claims, particularly for weight loss and anti-aging treatments.

Operator Impact

Med spa operators must verify state-specific ownership, supervision, and scope of practice requirements before opening. A medical director arrangement that is compliant in one state may be non-compliant in another.

Apply Market Intelligence to Your Business Strategy

Book a strategy session to discuss how current market trends apply to your specific practice model and growth objectives.

Book a Strategy Session

Methodology: Market statistics are sourced from cited publications and research at the time of publication. Projections reflect analyst estimates and are not guarantees of future performance. AJ's Take sections represent operator analysis and are clearly identified as such. This content does not constitute investment advice. Full editorial methodology.